The Jerusalem PostTIME names Israeli medical AI company Aidoc's CARE model amid Best Inventions of 2026PunchPolice arrest suspected serial burglar in Oyo, recover N16.2m stolen itemsRTP DesportoSurfista Mafalda Lopes vence final feminina do Peniche Pro20 MinutenGruppe belagert Halloween-Party – Polizei setzt Gummischrot einZDF heuteEntdecken Sie das ZDF-NachrichtenstudioSportstarIFL 2026/27: Nishu’s lone strike sees Sreenidi Deccan edge past Rajasthan United in season openerESPNKyler Murray's double-breasted look tops NFL Week 8's best arrivalsCollider‘Zootopia 3’ Will Officially Expand the Franchise in a New DirectionGuardian SportLiverpool v Arsenal: Premier League – liveynetליברמן לאיזנקוט: הקמפיין שלך פגע בסיכויי גוש השינוי בבחירותWirtualna PolskaPlanował zamach w Moskwie. FSB zatrzymało nastolatka po cynku z USAXatakaHoy en Lidl (por 6,99 euros) este pack de tres higrómetros con los que tener la humedad y temperatura de casa siempre bajo control
The Daily Newsstand · Free, Always
Sunday, November 1, 2026

TIME names Israeli medical AI company Aidoc's CARE model amid Best Inventions of 2026

Translate

Israeli medical technology company Aidoc's artificial intelligence model, CARE, has been named one of TIME magazine's Best Inventions of 2026 in the Medicine and Health category, the company announced in a statement.

The model analyzes medical imaging and clinical text to help doctors identify serious medical conditions at an earlier stage. TIME's selection panel highlighted the technology's ability to detect a wide range of potentially serious medical findings, one of the factors contributing to its inclusion on the list.

When the system detects a potentially urgent finding, it flags the examination so medical teams can prioritize it for review. The model also allows Aidoc to expand the number of conditions it can identify without developing a separate AI model for each one.

TIME's annual list recognizes inventions based on their originality, effectiveness, ambition, and impact. Other technologies featured on the 2026 list include Anthropic's Claude Code and Lovable.

Aidoc CEO and co-founder Elad Walach said advances in medical AI are bringing the technology closer to serving as an additional safeguard in routine medical diagnoses.

Illustration: A doctor uses artificial intelligence technology in their work.
Illustration: A doctor uses artificial intelligence technology in their work. (credit: INGIMAGE)

AI could serve as a second pair of eyes in medical diagnoses, Aidoc CEO says

"Medical foundation models that can detect hundreds of diseases and significantly improve diagnostic safety are among the developments that will affect us all," Walach said.

"We are rapidly approaching a reality in which AI will serve as an additional pair of eyes in almost every medical diagnosis. CARE is already a significant growth driver for Aidoc, and TIME's selection is an important recognition of this major trend."

Aidoc's AI solutions, which have received clearance from the US Food and Drug Administration (FDA), are used across more than 150 healthcare systems in the United States and over 1,600 hospitals worldwide, including most hospitals in Israel, the company said.

The CARE model is designed to allow the company to expand the range of medical conditions its technology can detect while improving the accuracy of its algorithms.

Aidoc's AI platform helps doctors identify life-threatening conditions in real time

Founded in 2016 by Walach, Michael Braginsky, and Guy Reiner, Aidoc has developed an AI-powered platform that analyzes medical imaging and other clinical data to alert doctors to potentially life-threatening conditions and help prioritize urgent cases in real time.

The company has raised more than $500 million since its founding, attracting investment from major venture capital firms, including General Catalyst, TLV Partners, Magma Emerge, Square Peg, SoftBank's Vision Fund 2, and NVentures, Nvidia's venture capital arm.

Its most recent funding round, totaling $150 million, closed in April 2026 and was led by Goldman Sachs' growth investment division.

View the original on The Jerusalem Post →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.